Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;32(5):710-726.e8.
doi: 10.1016/j.stem.2025.03.008. Epub 2025 Apr 9.

A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models

Affiliations
Free article

A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models

Chiara Pavan et al. Cell Stem Cell. .
Free article

Abstract

Human pluripotent stem cell (hPSC)-derived therapies are a realistic possibility for numerous disorders, including Parkinson's disease. While generating replacement neurons is achievable, immunosuppressive drug challenges, to prevent rejection, remain. Here we adopted a hPSC line (termed H1-FS-8IM), engineered to overexpress 8 immunomodulatory transgenes, to enable transplant immune evasion. In co-cultures, H1-FS-8IM PSC-derived midbrain neurons evaded rejection by T lymphocytes, natural killer cells, macrophages, and dendritic cells. In humanized mice, allogeneic H1-FS-8IM neural grafts evaded rejection, while control hPSC-derived neural grafts evoked activation of human immune cells, elevated inflammatory cytokines in blood and cerebrospinal fluid, and caused spleen and lymph node enlargement. H1-FS-8IM neural grafts retained functionality, reversing motor deficits in Parkinsonian rats. Additional incorporation of a suicide gene into the H1-FS-8IM hPSC line enabled proliferative cell elimination within grafts. Findings demonstrate feasibility of generating a population-wide applicable, safe, off-the-shelf cell product, suitable for treating diseases for which cell-based therapies are a viable option.

Keywords: Parkinson’s disease; allografting; dopamine; graft integration; graft rejection; human pluripotent stem cells; immune evasion; suicide gene; transplantation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.N. is an inventor on the patent application covering the induced Allogeneic Cell Tolerance (iACT Stealth) Technology (WO/2018/227286) and the patent covering the safe-cell (FailSafe) technology (PCT/CA2016/050256). A.N. is a co-founder and shareholder of panCELLa Inc, having exclusive license to the technology.

LinkOut - more resources